Barclays Starts Tarsus Pharmaceuticals (TARS) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TARS Hot Sheet
Price: $68.70 -5.42%
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Barclays analyst Glen Santangelo initiates coverage on Tarsus Pharmaceuticals (NASDAQ: TARS) with a Overweight rating and a price target of $100.00.
For an analyst ratings summary and ratings history on Tarsus Pharmaceuticals click here. For more ratings news on Tarsus Pharmaceuticals click here.
Shares of Tarsus Pharmaceuticals closed at $81.77 yesterday.
You May Also Be Interested In
- Tarsus Pharmaceuticals (TARS) PT Raised to $106 at H.C. Wainwright
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Bernstein SocGen Group Starts Abbott India Ltd (BOOT:IN) at Market Perform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
